Merck Faces $200 Million Tariff Hit and Gardasil Sales Decline

Tariff Impact on Merck

⚠️ Merck anticipates a $200 million loss in 2025 due to tariffs, primarily affecting imports from China and retaliatory tariffs on exports.
💡 This is particularly concerning for the pharmaceutical industry, which faces anxiety over potential specific pharmaceutical tariffs.
🔍 Analysts are probing companies like Merck about their exposure to pharmaceutical tariffs, but Merck has artfully dodged direct commitment.

🇨🇳 Merck faces challenges on two fronts: retaliatory tariffs from China impacting product sales and potential U.S. tariffs on pharmaceutical imports.
🏭 The company has a global manufacturing network, with intellectual property for key drugs like Keytruda located in Ireland, complicating import costs if U.S. tariffs are imposed.
📈 A hypothetical 25% U.S. tariff on pharmaceuticals could result in Merck paying significant costs to import its own products and IP back into the United States.

📉 Merck's stock is down 21% year-to-date, making it the worst performer among big pharma companies.
🎯 A primary concern is the significant decline in Gardasil vaccine sales in China, which fell 41% in the first quarter.
📉 Merck voluntarily halted all shipments of Gardasil to China due to built-up inventory and falling demand, potentially losing $3-4 billion annually from this market.

❓ The market is seeking a convincing explanation for the Gardasil decline and a clear plan to mitigate its impact.
🧩 Merck's business in China for Gardasil relies on a distributor, making it difficult for Merck to have direct insight into on-the-ground sales and market dynamics.
🚀 Investors are concerned about Merck's portfolio heading into the rest of the decade, especially with Keytruda facing patent cliffs and competition around 2028.
💡 The rise of Chinese biotech companies developing their own vaccines is also seen as a factor impacting Gardasil's market share.